News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ascentage Pharma Approved To Start China Trial Of Apoptosis Drug



7/19/2017 8:45:20 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
July 18, 2017 -- Ascentage Pharma was granted Investigational New Drug (IND) approval by the CFDA for APG-1252, a novel Bcl-2/Bcl-XL inhibitor. APG-1252, one of three programmed cell death candidates in Ascentage's development pipeline, started a Phase I trial in the US earlier this year. The trial will enroll patients with small cell lung cancer. Ascentage is headquartered in Hong Kong, but operates an R&D facility in Shanghai and a lab/manufacturing facility in Taizhou's China Medical City. The company raised $72 million in a B round in late 2016.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES